Cypherpunk Technologies reported a $37.8 million loss in the first half of 2026 despite holding 323,394 ZEC valued at about $157 million, more than double its $74 million market cap. The company is pivoting to fund Phase 3 trials for its cancer drug Sirexatamab, which failed to show benefits in Phase 2 but received FDA fast track status. With only $7.6 million in cash and ongoing losses, Cypherpunk faces a tough financial path, balancing its crypto asset accumulation goal with costly drug development. The company is seeking external funding options but has not secured any partnerships yet, raising investor concerns about its future.
Bitcoin has stabilized around $77,000 as the crypto market anticipates the Federal Reserve's interest rate decision this Wednesday, with a 90% chance of a 0.25% hike. After peaking at $81,200 in late August, Bitcoin retreated and consolidated in the ...
The Schwab U.S. Broad Market ETF (SCHB) currently holds about 2,380 U.S. stocks but has a high concentration risk, with 33.7% of its assets in the top 10 holdings and 36% in the technology sector. This concentration is increasingly hard to justify as...
Paxos' USDG stablecoin reached a remarkable $21.8 billion in trading volume on Uniswap during September, accounting for 98% of its decentralized exchange activity. This surge was driven by Uniswap's launch of the StablePair Hook, a dynamic fee system...
The Federal Reserve's first interest rate increase since 2023 is estimated to boost Interactive Brokers' annual revenue by about $81 million. This rate hike reflects the Fed's monetary policy shift and directly benefits brokerage firms like Interacti...
Russia's Moscow Exchange (MOEX) will launch perpetual futures contracts for XRP alongside Bitcoin, Ethereum, Solana, and TRON on September 22. These contracts, quoted in USD but settled in Russian rubles, allow qualified investors to gain price expos...
